Alto Ingredients, Inc.

NasdaqCM:ALTO Aktierapport

Börsvärde: US$410.4m

Alto Ingredients Förvaltning

Förvaltning kriterier kontrolleras 4/4

Alto Ingredients VD är Bryon McGregor, utsedd i Aug 2023, har en mandatperiod på 2.67 år. totala årliga ersättningen är $ 1.26M, bestående av 42.5% lön 57.5% bonusar, inklusive företagsaktier och optioner. äger direkt 1.24% av företagets aktier, värda $ 5.09M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.7 år respektive 3.8 år.

Viktig information

Bryon McGregor

Verkställande direktör

US$1.3m

Total ersättning

VD-lön i procent42.54%
Anställning som VD2.7yrs
Ägande av VD1.2%
Ledningens genomsnittliga anställningstid2.7yrs
Styrelsens genomsnittliga mandatperiod3.8yrs

Senaste uppdateringar av ledningen

Recent updates

ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential

Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.

ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data

Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.

ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline

Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.

ALTO: Future Returns Will Depend On Execution And Funding Discipline

Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.

ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution

Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.

ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution

Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.

ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile

Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.

ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile

Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.

ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook

Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.

Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story

Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story

ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead

Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.

Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth

Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth

Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%

Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
User avatar

CO2 Plant Integration Will Boost Production And Exports

Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.

Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?

Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?

Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt

Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt

Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?

Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?

Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt

Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt

Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?

Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?

We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt

Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt

Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?

Dec 16
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?

Alto Ingredients: The Decline Has Created A Buying Opportunity

Oct 19

Alto Ingredients gains on announcing $50M share repurchase program

Sep 12

Alto Ingredients (NASDAQ:ALTO) Seems To Use Debt Quite Sensibly

Aug 31
Alto Ingredients (NASDAQ:ALTO) Seems To Use Debt Quite Sensibly

Alto Ingredients: Cheap For A Reason

Jul 31

With EPS Growth And More, Alto Ingredients (NASDAQ:ALTO) Makes An Interesting Case

Jun 18
With EPS Growth And More, Alto Ingredients (NASDAQ:ALTO) Makes An Interesting Case

Analys av ersättningar till VD

Hur har Bryon McGregor:s ersättning förändrats jämfört med Alto Ingredients:s resultat?
DatumTotal ersättningLönFöretagets resultat
Dec 31 2025n/an/a

US$12m

Sep 30 2025n/an/a

-US$51m

Jun 30 2025n/an/a

-US$68m

Mar 31 2025n/an/a

-US$60m

Dec 31 2024US$1mUS$537k

-US$60m

Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$1mUS$427k

-US$29m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$53m

Dec 31 2022US$720kUS$352k

-US$43m

Sep 30 2022n/an/a

US$26m

Jun 30 2022n/an/a

US$51m

Mar 31 2022n/an/a

US$37m

Dec 31 2021US$910kUS$336k

US$44m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

US$7m

Mar 31 2021n/an/a

US$13m

Dec 31 2020US$482kUS$331k

-US$16m

Sep 30 2020n/an/a

-US$37m

Jun 30 2020n/an/a

-US$80m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$401kUS$318k

-US$90m

Ersättning vs marknad: Bryon s total kompensation ($USD 1.26M ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 2.48M ).

Ersättning vs inkomst: Ersättningen från Bryon har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Bryon McGregor (61 yo)

2.7yrs
Anställning
US$1,262,735
Kompensation

Mr. Bryon T. McGregor served as Chief Financial Officer of Alto Ingredients, Inc. (formerly known as Pacific Ethanol, Inc.) (formerly Aventine Renewable Energy Holdings, Inc.) since November 19, 2009 until...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Bryon McGregor
CEO, President & Director2.7yrsUS$1.26m1.24%
$ 5.1m
Robert Olander
Chief Financial Officer2.7yrsUS$640.05k0.33%
$ 1.3m
Todd Benton
Chief Operating Officer2yrsUS$609.36k0.24%
$ 977.7k
Auste Graham
Chief Legal Officer & Secretary4.2yrsUS$614.56k0.33%
$ 1.3m
James Sneed
VP & Chief Commercial Officerno dataUS$604.90k0.57%
$ 2.3m
Ed Baker
Vice President of Human Resourcesno datainga uppgifteringa uppgifter
2.7yrs
Genomsnittlig anställningstid
51yo
Genomsnittlig ålder

Erfaren ledning: ALTO s ledningsgrupp anses vara erfaren ( 2.7 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Bryon McGregor
CEO, President & Director1.8yrsUS$1.26m1.24%
$ 5.1m
Alan Tank
Independent Directorless than a yearinga uppgifter0.047%
$ 194.7k
Dianne Nury
Vice-Chair of the Board6.4yrsUS$148.03k0.28%
$ 1.2m
Gilbert Nathan
Independent Chairman of the Board6.4yrsUS$148.03k1.01%
$ 4.1m
Maria Gray
Independent Director3.8yrsUS$148.03k0.20%
$ 826.4k
3.8yrs
Genomsnittlig anställningstid
61yo
Genomsnittlig ålder

Erfaren styrelse: ALTO s styrelse anses vara erfaren ( 3.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/04/30 03:09
Aktiekurs vid dagens slut2026/04/30 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Alto Ingredients, Inc. bevakas av 9 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Carter DriscollB. Riley Securities, Inc.
Hamed KhorsandBWS Financial Inc.
Eric StineCraig-Hallum Capital Group LLC